Beda Pharmaceuticals" Ektinib's New Adaptation Report is listed for postoperative ancillary therapy.

Ektini is the first small molecule with independent intellectual property rights independently developed by Beda Pharmaceuticals to target anti-cancer drugs, its efficacy is accurate, low hepatotoxicity, high safety, evidence-based medical clinical evidence is rich, Chinese groups of data, in CSCO guidelines, wei Health care norms and brain transfer population, 21-L858R NSCLC patients were recommended as a priority, is currently the only one to continue the follow-up free drug program of the generation of EGFR-TKI original research drugs, with obvious differentiation advantages.
Currently, Ektini has been approved for two adaptations: (1) single drug for the treatment of patients with local late stage or metastasis non-small cell lung cancer with sensitive mutations in the skin growth factor recipient (EGFR) gene;
The application for a listing license for EKTinib's postoperative assisted therapy adaptation in NSCLC patients with EGFR gene-sensitive mutations was based on the EVIDENCE study, which was a controlled trial of postoperative assisted therapy in patients with EGFR mutations in stage II.-IIIA lung cancer, with Ektini therapy in the experimental group and standard assisted chemotherapy in the control group.
nearly 6 years of the project, the results showed that ektinist was more effective than standard complementary chemotherapy, which significantly extended patients' disease-free survival and improved safety.
as of this announcement date, there are no approved EGFR-TKI targeted drugs for postoperative ancillary therapy in patients with EGFR gene-sensitive mutation NSCLC.
.